Address: 119530, Russia, Moscow, Generala Dorokhova str., 18-2,Russia
Tel: +7 495 933 60 80
Valenta was founded in 1997 as “Otechestvennye lekarstva” and presently includes JSC Valenta Pharmaceuticals.
The holding is consistently carrying out its social responsibility policy, by developing and implementing socially important projects aimed at improvement of life quality and longevity of Russian people.
Valenta is one of the largest pharmaceutical manufacturer in Russia. Being the first means being fully responsible towards our shareholders, business partners, consumers, and our own employees.
Over 1500 people are working in our holding today in the plant in Schelkovo and in our head office in Moscow. Medical representatives working in all large cities of Russia are among them.
We want to prove, with our work, originality and quality of our medicines, corporate management and manufacturing standards, that Valenta is not only the largest but the best pharmaceutical company in Russia.
Valenta is power, attraction, ability to adapt to ever changing business environment and the world, we are moving with the time and market trends. We changed the name of our company, but we do not abandon our main principles: development of innovative medicines, support of Russian science, investments into the health of the nation.
Main pharmacotherapeutic groups
• antibacterial
• neurological
• vitaminis
• cardiological
• antihistamine
• parenteral feeding, etc.
Valenta was established in 1997 as Otechestvennye Lekarstva, and today represents the consolidation of several facilities and business holding groups. Can you give our readers an overview of the company’s…
Valenta was established in 1997 as Otechestvennye Lekarstva, and today represents the consolidation of several facilities and business holding groups. Can you give our readers an overview of the company’s…
Since 2006, Russia has witnessed quite a dynamic few years, with sweeping legislative reforms like the Law on Circulation of Medicines and development strategies like Pharma 2020. What have been…
Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your…
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Ferring is a specialty biopharmaceutical company that operates in four strategic therapeutic areas. Globally, many pharma companies have been diversifying their portfolio, and entering the OTC segment, generics segment, medical…
Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of…
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
The AEB works through a number of channels to promote the interests of European corporations with operations in Russia. It has a long history in this country, dating back to…
Novo Nordisk announced last year the development of an insulin plant in the Kaluga region not far from Moscow. What is the strategic significance of this plant, both for the…
Many expat managers have used Russia as a stepping-stone, but you have headed this business for an astounding 9 years. What is it about this country and about Reckitt Benckiser’s…
See our Cookie Privacy Policy Here
